trending Market Intelligence /marketintelligence/en/news-insights/trending/Zjalx8yICwHFtS4VHDB3mQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

KemPharm's acute pain drug gains FDA fast-track designation

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


KemPharm's acute pain drug gains FDA fast-track designation

The U.S. FDA granted fast-track designation to KemPharm Inc.'s co-lead product candidate, KP201/IR, for the treatment of acute pain.

The company plans to start human clinical trials of the product in the first half of 2017.

KemPharm remains on target for the potential submission of a new drug application for KP201/IR in 2018, President and CEO Travis Mickle said in a statement.